Article info
Cancer genetics
Original article
Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)
- Correspondence to K Newton, Genomic Diagnostics Laboratory, Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, Saint Mary's Hospital, Oxford Road, Manchester M13 9WL UK; Katynewton2012{at}doctors.org.uk
Citation
Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC)
Publication history
- Received May 27, 2014
- Revised September 3, 2014
- Accepted September 10, 2014
- First published October 3, 2014.
Online issue publication
April 27, 2016
Article Versions
- Previous version (27 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions